Beyond Air, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $XAIR in the last 7 days.
No SEC Form 4 filings for $XAIR in the last 30 days.
See all $XAIR insider activity →Beyond Air (XAIR) received a 'Buy' rating and $10 price target from Lake Street. Analysts see potential in its nitric oxide delivery systems, but the company faces financial challenges, with a GF Score of 23/100 and a market cap of $3.75M. Insiders recently bought shares, and the stock is deemed 99.1% undervalued by GF Value.
Beyond Air (XAIR) received FDA Breakthrough Device Designation for LungFit GO, a portable nitric oxide therapy for NTM-PD. A pilot study showed safety, compliance, and quality-of-life improvements. The designation may accelerate clinical studies. XAIR closed at $4.48, up 4.10% in pre-market trading.
Beyond Air (XAIR) agreed to sell its 58% stake in NeuroNOS to UNIVO for equity and milestone payments. Beyond Air will receive 19.99% of UNIVO's shares and warrants, plus up to $32.5M in milestone payments. XAIR closed at $4.91, down 2.58%.
Recent XAIR coverage spans earnings, market movers and insider activity.
Analyst initiation may lift sentiment and support a price rally toward the $10 target.
Potential acceleration of regulatory path and market adoption for the device.
The deal dilutes existing shareholders but provides cashless equity and potential upside from UNIVO performance.
Risk of delisting creates bearish pressure.
The filing adds a concrete capital raise and keeps revenue guidance anchored to an FDA decision window, shifting near-term risk toward regulatory timing and funding runway.
AlphAI scores every news story that mentions XAIR with an AI model for sentiment and relevance, and aggregates insider trades from Beyond Air, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Beyond Air (XAIR) received a 'Buy' rating and $10 price target from Lake Street. Analysts see potential in its nitric oxide delivery systems, but the company faces financial challenges, with a GF Score of 23/100 and a market cap of $3.75M. Insiders recently bought shares, and the stock is deemed 99.1% undervalued by GF Value.
2 min readBeyond Air (XAIR) received FDA Breakthrough Device Designation for LungFit GO, a portable nitric oxide therapy for NTM-PD. A pilot study showed safety, compliance, and quality-of-life improvements. The designation may accelerate clinical studies. XAIR closed at $4.48, up 4.10% in pre-market trading.
2 min readBeyond Air (XAIR) agreed to sell its 58% stake in NeuroNOS to UNIVO for equity and milestone payments. Beyond Air will receive 19.99% of UNIVO's shares and warrants, plus up to $32.5M in milestone payments. XAIR closed at $4.91, down 2.58%.
2 min readLucid Group (LCID), Beyond Air (XAIR), and Conagra Brands (CAG) hit 52-week lows. LCID's outlook weakened due to lower revenue expectations and a stock offering, with analysts cutting price targets. XAIR received a Nasdaq compliance notice, while CAG faces earnings pressure from inflation and a recent CEO change.
2 min readBeyond Air, Inc. (XAIR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Beyond Air ® Reports Financial Results for the Quarter Ended June 30, 2026 and Provides Corporate Update Reports $1.8 million revenue for quarter ended June 30, 2026; reaffirms revenue guidance of $8 million for CY2026 and $16-$18 million for CY2027 PMA supplement fo
6 min readBeyond Air (XAIR) held a Q1 2027 earnings call. It reported Q ended June 30, 2026 revenue of $1.8 million, flat vs the prior quarter, with gross margin rising to 13% from 9%. The company reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16 million to $18 million, pending FDA approval for its Gen II LungFit PH system. It also entered a national GPO deal and announced financing up to $30 million.
6 min readBeyond Air (NASDAQ: XAIR) reported Q2 2026 revenue of $1.8 million and gross margin of 13%. It reaffirmed 2026 revenue guidance of $8 million and 2027 guidance of $16-$18 million, including second-generation LungFit PH revenue pending FDA approval. The company is awaiting FDA review of a PMA supplement, expects a decision in 2H 2026, and raised up to $30.1 million.
6 min readBiotech gainers on Monday included Universe Pharmaceuticals (UPC), which reported six-month ended March 31, 2026 revenue of $9.03 million and net loss of $1.55 million, and shares rose about 99% to $6.48. Cumberland Pharma (CPIX) rose over 38% ahead of Q2 results after a $100 million branded portfolio sale. Autolus (AUTL) gained about 22% on preliminary Q2 Aucatzyl net product revenue of about $45 million. Other movers included Pulmonx (LUNG), SL Science (SLBT), CAMP4 (CAMP), and Beyond Air (XAI
3 min readGoodman Robert Scott (Chief Executive Officer) purchased 34,722 shares of Beyond Air, Inc. (XAIR) at $5.76 ($0.20M total) on 2026-07-29.
2 min readMOORHEAD DANIEL J (Chief Financial Officer) purchased 4,340 shares of Beyond Air, Inc. (XAIR) at $5.76 on 2026-07-29.
2 min read
